Free biotech catalyst calendar
Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.
250 programs as of
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
These records could not be loaded. Open a numbered page to read the original quotations and SEC links.
Window ends in: 2026
Grouped by the period end. The company's wording is retained in each row; no countdown is shown.
Period the company stated: 2026
at a medical congress in 2026Details
Beam Therapeutics Inc. (BEAM) · BEAM-302
Stage: Not stated
Public float (as of ): $1.7B (SEC filing) · $500M–$2B
Period the company stated: 2026
updated BEAM-302 data at a medical congress in 2026
Period the company stated: year-end 2026
BEACON clinical trial by year-end 2026Details
Beam Therapeutics Inc. (BEAM) · risto-cel
Stage: Not stated
Public float (as of ): $1.7B (SEC filing) · $500M–$2B
Period the company stated: year-end 2026
We expect to report updated data for the BEACON clinical trial by year-end 2026
Period the company stated: end of 2026
in SLE expected by end of 2026Details
BIOGEN INC. (BIIB) · litifilimab
Stage: Not stated
Public float (as of ): $18.3B (SEC filing) · Over $2B
Period the company stated: end of 2026
Registrational data for litifilimab in SLE expected by end of 2026
Earlier SEC statements (1)
- · “data now expected in 2026 from both SLE studies for litifilimab which are fully enrolled.” · SEC filing
- CGEMCullinan Therapeutics · zipalertinib + platinum-based chemotherapyNDA/BLA submission MatchedSEC ↗Watch
Period the company stated: year-end 2026
submission is expected by year-end 2026.Details
Cullinan Therapeutics, Inc. (CGEM) · zipalertinib + platinum-based chemotherapy
Stage: Not stated
Public float (as of ): $442M (SEC filing) · Under $500M
Period the company stated: year-end 2026
Completion of the Company's NDA submission is expected by year-end 2026.
Period the company stated: end of 2026
results expected by end of 2026Details
Cogent Biosciences, Inc. (COGT) · bezuclastinib
Stage: Not stated
Public float (as of ): $772M (SEC filing) · $500M–$2B
Period the company stated: end of 2026
SUMMIT extension trial with preliminary results expected by end of 2026
Period the company stated: by the end of 2026
to be presented by the end of 2026.Details
CytomX Therapeutics, Inc. (CTMX) · varsetatug masetecan / CX-2051
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $372M (SEC filing) · Under $500M
Period the company stated: by the end of 2026
Additional Phase 1 Varseta-M data, including data from ongoing dose optimization, is anticipated to be presented by the end of 2026.
Earlier SEC statements (1)
- · “Additional Phase 1 Varseta-M data, including data from ongoing dose optimization, is anticipated to be presented in the second half of 2026.” · SEC filing
Period the company stated: year-end 2026
safety data expected by year-end 2026.Details
PRECISION BIOSCIENCES INC (DTIL) · PBGENE-DMD
Stage: OtherSEC filing · “Phase 1/2”
Public float (as of ): $47M (SEC filing) · Under $500M
Period the company stated: year-end 2026
The study is actively recruiting patients at specialized Duchenne care centers with initial safety data expected by year-end 2026.
ClinicalTrials.gov NCT07429240 · NCT stated in SEC filing
Earlier SEC statements (7)
- · “The study is actively recruiting patients with initial safety data expected for year-end 2026.” · SEC filing
- · “The study is actively recruiting patients with initial safety data expected for year-end 2026.” · SEC filing
- · “Initial data from multiple patients is expected by year end 2026, with safety and early efficacy assessed by the percentage of near full-length dystrophin protein expression from muscle biopsies.” · SEC filing
- · “Initial data from multiple patients is expected by year-end 2026, including safety and early efficacy assessment based on near full-length dystrophin protein expression from muscle biopsies.” · SEC filing
- · “initial clinical data expected in the second half of 2026.” · SEC filing
- · “initial clinical data expected in 2026.” · SEC filing
- · “clinical data expected in 2026.” · SEC filing
Period the company stated: end of 2026
to submit an NDA by the end of 2026Details
Eton Pharmaceuticals, Inc. (ETON) · AMGLIDIA
Stage: Not stated
Public float (as of ): $360M (SEC filing) · Under $500M
Period the company stated: end of 2026
remains on track to submit an NDA by the end of 2026
Period the company stated: 2026
data for IM-1021 in 2026Details
Immunome Inc. (IMNM) · IM-1021
Stage: Not stated
Public float (as of ): $728M (SEC filing) · $500M–$2B
Period the company stated: 2026
initial lymphoma data for IM-1021 in 2026
Earlier SEC statements (5)
- · “initial lymphoma data in 2026” · SEC filing
- · “initial lymphoma data for IM-1021 in 2026” · SEC filing
- · “lymphoma data expected in 2026” · SEC filing
- · “initial lymphoma data for IM-1021 in 2026” · SEC filing
- · “lymphoma patients treated with IM-1021, and we plan to share initial data in 2026” · SEC filing
Period the company stated: 2026
is anticipated in 2026.Details
IONIS PHARMACEUTICALS INC (IONS) · pelacarsen
Stage: Not stated
Public float (as of ): $5.2B (SEC filing) · Over $2B
Period the company stated: 2026
Pelacarsen Lp(a)-CVD Lp(a) HORIZON data •
SEC timing legend:
• Indicates that the milestone is anticipated in 2026.
Period the company stated: 2026
is anticipated in 2026.Details
IONIS PHARMACEUTICALS INC (IONS) · sefaxersen
Stage: Not stated
Public float (as of ): $5.2B (SEC filing) · Over $2B
Period the company stated: 2026
Sefaxersen IgAN IMAGINATION data •
SEC timing legend:
• Indicates that the milestone is anticipated in 2026.
Period the company stated: 2026
is anticipated in 2026.Details
IONIS PHARMACEUTICALS INC (IONS) · ulefnersen
Stage: Not stated
Public float (as of ): $5.2B (SEC filing) · Over $2B
Period the company stated: 2026
Ulefnersen FUS-ALS FUSION data •
SEC timing legend:
• Indicates that the milestone is anticipated in 2026.
Period the company stated: year-end 2026
readout by six months to year-end 2026Details
Kymera Therapeutics, Inc. (KYMR) · KT-621
Stage: Not stated
Public float (as of ): $2.2B (SEC filing) · Over $2B
Period the company stated: year-end 2026
its expected topline data readout by six months to year-end 2026
Earlier SEC statements (2)
- · “BROADEN2 Phase 2b AD trial in 2026, with data expected to be reported by mid-2027” · SEC filing
- · “BROADEN2 Phase 2b trial in AD has been initiated with topline data expected by mid-2027” · SEC filing
Period the company stated: 2026
to be generated in 2026.Details
Lineage Cell Therapeutics, Inc. (LCTX) · COR1
Stage: OtherSEC filing · “preclinical”
Public float (as of ): $161M (SEC filing) · Under $500M
Period the company stated: 2026
Lineage has also elected to advance the COR1 program into in-vivo animal testing with initial preclinical data expected to be generated in 2026.
Period the company stated: 2026
data potentially in 2026Details
Moderna, Inc. (MRNA) · intismeran autogene
Stage: Phase 3SEC filing · “Phase 3”
Public float (as of ): $9.9B (SEC filing) · Over $2B
Period the company stated: 2026
Phase 3 adjuvant melanoma data potentially in 2026
Period the company stated: 2026
data expected in 2026, subject to case accrualsDetails
Moderna, Inc. (MRNA) · mRNA-1403
Stage: Not stated
Public float (as of ): $9.9B (SEC filing) · Over $2B
Period the company stated: 2026
data expected in 2026, subject to case accruals
Period the company stated: 2026
We expect potential data in 2026Details
Moderna, Inc. (MRNA) · mRNA-3927
Stage: Not stated
Public float (as of ): $9.9B (SEC filing) · Over $2B
Period the company stated: 2026
We expect potential data in 2026
Earlier SEC statements (1)
- · “data expected in 2026” · SEC filing
Period the company stated: 2026
Phase 2 data readout in 2026Details
Moderna, Inc. (MRNA) · mRNA-4359
Stage: Phase 2SEC filing · “Phase 2”
Public float (as of ): $9.9B (SEC filing) · Over $2B
Period the company stated: 2026
we expect a potential Phase 2 data readout in 2026
Earlier SEC statements (3)
- · “Phase 2 data readout in 2026” · SEC filing
- · “Phase 2 data readout in 2026” · SEC filing
- · “Phase 2 data readout in 2026” · SEC filing
Period the company stated: 2026
at a medical conference in 2026.Details
Nkarta, Inc. (NKTX) · NKX019
Stage: Not stated
Public float (as of ): $82M (SEC filing) · Under $500M
Period the company stated: 2026
Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical conference in 2026.
ClinicalTrials.gov NCT06557265 · NCT stated in SEC filing
ClinicalTrials.gov NCT06733935 · NCT stated in SEC filing
Earlier SEC statements (2)
- · “Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical conference in 2026.” · SEC filing
- · “Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026” · SEC filing
Period the company stated: year-end 2026
interim clinical update by year-end 2026Details
ONCOLYTICS BIOTECH INC (ONCY) · pelareorep
Stage: Not stated
Public float (as of ): $72M (SEC filing) · Under $500M
Period the company stated: year-end 2026
Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026
Earlier SEC statements (1)
- · “It also expects to report an initial tumor response update from patients enrolled in Part A by year-end 2026” · SEC filing
Period the company stated: 2026
of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European GastroenterologyDetails
PALISADE BIO, INC. (PALI) · PALI-2108
Stage: Not stated
Public float (as of ): $11M (SEC filing) · Under $500M
Period the company stated: 2026
Additional PALI-2108 data to be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European Gastroenterology (UEG) Week 2026.
- RANIRani Therapeutics Holdings · RT-114 / PG-102 via RaniPill HCTopline/data readout MatchedSEC ↗Watch
Period the company stated: by the end of 2026
expansion cohort expected by the end of 2026.Details
Rani Therapeutics Holdings, Inc. (RANI) · RT-114 / PG-102 via RaniPill HC
Stage: Not stated
Public float (as of ): $65M (SEC filing) · Under $500M
Period the company stated: by the end of 2026
We have continued to advance the program in the clinic, with additional data from the dose expansion cohort expected by the end of 2026.
Period the company stated: 2026
readouts for casdatifan in 2026:Details
Arcus Biosciences, Inc. (RCUS) · casdatifan
Stage: Not stated
Public float (as of ): $565M (SEC filing) · $500M–$2B
Period the company stated: 2026
In second-line IO-experienced ccRCC, more mature overall response rate data and initial PFS data, including Kaplan-Meier curve(s), for approximately 45 patients treated in the ARC-20 cohort evaluating casdatifan plus cabozantinib. All patients will have had at least 18 months of follow-up.
SEC timing context:
Arcus expects multiple data readouts for casdatifan in 2026:
Period the company stated: 2026
readouts for casdatifan in 2026:Details
Arcus Biosciences, Inc. (RCUS) · casdatifan
Stage: Not stated
Public float (as of ): $565M (SEC filing) · $500M–$2B
Period the company stated: 2026
early efficacy data for the cohort evaluating casdatifan plus zimberelimab
SEC timing context:
Arcus expects multiple data readouts for casdatifan in 2026:
Period the company stated: 2026
readouts for casdatifan in 2026:Details
Arcus Biosciences, Inc. (RCUS) · casdatifan
Stage: Not stated
Public float (as of ): $565M (SEC filing) · $500M–$2B
Period the company stated: 2026
early safety data for the cohort evaluating casdatifan plus zimberelimab plus ipilimumab
SEC timing context:
Arcus expects multiple data readouts for casdatifan in 2026:
Period the company stated: 2026
readouts for casdatifan in 2026:Details
Arcus Biosciences, Inc. (RCUS) · casdatifan
Stage: Not stated
Public float (as of ): $565M (SEC filing) · $500M–$2B
Period the company stated: 2026
In late-line ccRCC, updated data from the ARC-20 monotherapy cohorts, including overall survival data.
SEC timing context:
Arcus expects multiple data readouts for casdatifan in 2026:
Period the company stated: end of 2026
HCC data by the end of 2026.Details
Replimune Group, Inc. (REPL) · RP2
Stage: Not stated
Public float (as of ): $234M (SEC filing) · Under $500M
Period the company stated: end of 2026
The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.
Earlier SEC statements (3)
- · “The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” · SEC filing
- · “The protocol has been amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” · SEC filing
- · “The protocol is currently being amended to include RP2 as monotherapy and we plan to release preliminary HCC data by the end of 2026.” · SEC filing
Period the company stated: 2026
publication of the data in 2026.Details
Replimune Group, Inc. (REPL) · TUDRIQEV (RP1)
Stage: Not stated
Public float (as of ): $234M (SEC filing) · Under $500M
Period the company stated: 2026
We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.
Earlier SEC statements (3)
- · “We have closed enrollment in the ARTACUS trial and are planning a publication of the data in 2026.” · SEC filing
- · “We are planning a publication of the ARTACUS data in 2026.” · SEC filing
- · “We continue to enroll patients into the ARTACUS trial and are planning a publication of the ARTACUS data in 2026.” · SEC filing
Period the company stated: by the end of 2026
phase of the study by the end of 2026.Details
RIGEL PHARMACEUTICALS INC (RIGL) · R289
Stage: Not stated
Public float (as of ): $331M (SEC filing) · Under $500M
Period the company stated: by the end of 2026
We anticipate sharing preliminary data from the dose expansion phase of the study by the end of 2026.
Earlier SEC statements (1)
- · “The company anticipates sharing preliminary data from the dose expansion phase of the study by the end of 2026.” · SEC filing
Period the company stated: 2026
and research congresses in 2026.Details
Silence Therapeutics plc (SLN) · SLN312
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $206M (SEC filing) · Under $500M
Period the company stated: 2026
Phase 1 data presentations are planned for medical and research congresses in 2026.
No program matches these filters. Ask for a company on the Watch page.
About this calendar
FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.
Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.
How this calendar is made
- Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
- Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
- Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
- Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
- Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
- Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
- Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
- Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
- Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
- “Wording changed” opens the earlier sentences, each with its date and filing.
- No forecast, price, score or signal. The calendar repeats what companies wrote.
Want an email when one of these changes? Get a free Watch.
Window ended
The company-stated period has ended. These records retain their wording and filing links.
1 programs as of
No ended windows match these filters.
Timing without a stated calendar date
These SEC statements retain an ambiguous period or an event trigger. No date or countdown is assigned.
3 records as of
No records match these filters. Choose All periods to view timing without a calendar date.
Results disclosed
An SEC resolution filing is held in these records. The original schedule, quote and source remain available.
47 programs as of
No disclosed records match these filters.